Skip to main content
Premium Trial:

Request an Annual Quote

Stanley Rose New NimbleGen CEO; Gualberto Ruano Launches New Company; Life Sciences Prominent in TR100; and Others

NEW YORK Sept. 17 (GenomeWeb News) - Stanley Rose has been appointed president and CEO of NimbleGen Systems, the Madison, Wis., microarray company said today.


Rose, who will also serve on the company's board of directors, comes to NimbleGen from OpGen, also of Madison, where he is currently chairman of the board. He is also a director of Madison-based GeneTel Biosurfaces. Previously, he founded Genetic MicroSystems, which produced microarray scanners and was acquired by Affymetrix in 2000. He has also worked in the PCR business at PerkinElmer and Applied Biosystems.


Gualberto Ruano, who resigned from his post as vice chairman and chief scientific officer of Genaissance Pharmaceuticals Aug. 31, has launched a new company, Genomas, the Hartford Courant reported Sept. 16.


Genomas, based in New Haven, Conn., will focus on pharmacogenomics, studying individual genetic responses to stress, exercise, climate, and disease, in order to formulate individual diet, exercise and medical treatment that is genome-based, the news story said.


The company has not received outside funding, and is being run from Ruano's home office. Ruano is collaboratng with cardiologist Paul Thompson at Hartford Hospital, according to the report. 


Ruano founded Genaissance in 1997, and served as president and CEO until Aug. 2002, when the company announced a round of restructuring and layoffs. At that time, COO Kevin Rakin was promoted to CEO, and Ruano became CSO and vice chairman of the company.


This move comes less than a month after Ruano divested himself of over 460,000 shares of Genaissance stock, netting proceeds of approximately $550,000.


Serafim Batzoglou, Eugene Chan, Christophe Echeverri, Jay Groves, Gavin MacBeath, Christophe Schilling, Micah Siegal, and Daphne Zohar are among this year's top 100 young innovators being honored by MIT's Technology Review magazine.


The innovators, who were selected by the magazine's editors and a panel of judges, and must as a rule be all under age 35, will be honored Sept. 24-25 at the Emerging technologies Conference at MIT. Detailed bios are also be published in the October issue of the magazine, which became available online this week.


Batzoglou was named for the development of his genomic assembly program Arachne, released in 2002, which enables users to assemble gene fragments into full genome, as well as Rosetta, which is designed for comparison of mouse and human genomes.  Batzoglou developed Arachne and Rosetta while at MIT's laboratory for computer science, and is now an assistant professor of computer science at Stanford University. His current project is Lagan, which involves alignment of long sequences of DNA for comparison of human and other genomes.


Chan was recognized for founding US Genomics, of Woburn, Mass., which is aiming to develop technology for sequencing of the 10-minute genome.


Echeverri was chosen due to his work as the founder, CEO, and chief scientific officer of Cenix Bioscience of Dresden, Germany, which performs drug discovery services for researchers using RNA interference technology and has raised 11 million euro.


Groves was cited for his work with Synamem, formerly Proteomic Systems, which has developed a "membrane chip" technology-and array of cellular membranes for drug discovery.


MacBeath, who is an assistant professor at Harvard University's department of chemistry and chemical biology, is being recognized for his work developing technology for Merrimack Pharmaceuticals. Merrimack, founded in 2000 and based in Cambridge. Mass., does drug discovery based on an approach it calls "network biology," - the study of networks of proteins and the interactions mediating cellular pathways.


Schilling was named because he co-founded Genomatica, a computational systems biology company, in 2000, while a graduate student at The University of California, San Diego, along with his professor, Bernhard Palsson. He is now chief technical officer of the company.


Siegal was chosen because he is the co-founder of Concept2Company, of Palo Alto, Calif., which has the mission of helping scientists found companies based on their ideas and innovations without quitting their day jobs.


Zohar was chosen due to her work as the founder and managing general partner of PureTech Ventures, a Boston-based life sciences venture capital firm.


Len Hendrickson, president and CEO of BioSource, has taken an indefinite medical disability leave of absence, the life sciences reagent company said Sept. 11.


Robert Weltman, who is currently on the board of directors, has been appointed interim CEO by the board while the company seeks a longer-term replacement for Hendrickson.


Weltman, who has served on BioSource's board since February 2000, is currently general partner at GenStar Capital Partners, a private equity limited partnership. Weltman is also on the board of PRA International, a clinical research organization, and also was on the board of NEN Life Science Products prior to its acquisition by PerkinElmer in 2000.




The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.